Cited by 573Angiogenesis and VEGF in CancerColorectal Cancer Treatments and StudiesBreast Cancer Treatment Studies

The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.

Biomarkers of response and resistance to antiangiogenic therapy

Open access

Jain, Rakesh K., Duda, Dan G., Willett, Christopher G., Sahani, Dushyant V., Zhu, Andrew X., Loeffler, Jay S., Batchelor, Tracy T., Sorensen, A. Gregory·2009·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2009.63PMC PMC3057433

Open this paper in CoChat — free account

Abstract

No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2009.63

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citation
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citation
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622

Flagged first, then by citations

Show all 83 references

1 of the 83 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 573

Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies
de Mello, R. A. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i11.367 · Cited by 43
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24
Goodwin, R. A., Ding, K., Seymour, L., LeMaître, A., Arnold, A., Shepherd, F. A., Dediu, M., Ciuleanu, T., Fenton, D. W., Zukin, M., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq221 · Cited by 44
Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment
Melling, N., Grüning, A., Tachezy, M., Nentwich, M. F., Reeh, M., Uzunoglu, F. G., Vashist, Y. K., Izbicki, J. R., & Bogoevski, D. (2016) · Surgery · doi:10.1016/j.surg.2016.01.018 · Cited by 44
Bevacizumab Biosimilars: Scientific Justification for Extrapolation of Indications
Melosky, B. L., Reardon, D. A., Nixon, A. B., Subramanian, J., Bair, A. H., & Jacobs, I. A. (2018) · Future Oncology · doi:10.2217/fon-2018-0051 · Cited by 44
Microvascular morphometrics of the hypophysis and pituitary tumors: From bench to operating theatre
Ieva, A. D., Weckman, A. M., Michele, J. D., Rotondo, F., Grizzi, F., Kovács, K., & Cusimano, M. D. (2013) · Microvascular Research · doi:10.1016/j.mvr.2013.04.009 · Cited by 43
Targeting angiogenesis with compounds from the extracellular matrix
Belotti, D., Foglieni, C., Resovi, A., Giavazzi, R., & Taraboletti, G. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.08.012 · Cited by 44
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti‐angiogenic drug effects
Lemasson, B., Christen, T., Tizon, X., Farion, R., Fondraz, N., Provent, P., Segebarth, C. M., Barbier, E., Genne, P., Duchamp, O., et al. (2010) · NMR in Biomedicine · doi:10.1002/nbm.1611 · Cited by 43
Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)
Raut, C. P., Boucher, Y., Duda, D. G., Morgan, J. A., Quek, R. H. H., Ancukiewicz, M., Lahdenranta, J., Eder, J. P., Demetri, G. D., & Jain, R. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0026331 · Cited by 44
Self-citation
Cooperative multi-targeting of signaling networks by angiomiR-204 inhibits vasculogenic mimicry in breast cancer cells
Salinas-Vera, Y. M., Marchat, L. A., García-Vázquez, R., la Rosa, C. H. G.-D., Castañeda-Saucedo, E., Navarro‐Tito, N., Flores, C. P., Pérez‐Plasencia, C., Cruz-Colín, J. L., Carlos‐Reyes, Á., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.003 · Cited by 43
Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181af5e35 · Cited by 43
Self-citation
Upregulation of adipocyte enhancer‐binding protein 1 in endothelial cells promotes tumor angiogenesis in colorectal cancer
Yorozu, A., Yamamoto, E., Niinuma, T., Tsuyada, A., Maruyama, R., Kitajima, H., Numata, Y., Kai, M., Sudo, G., Kubo, T., et al. (2020) · Cancer Science · doi:10.1111/cas.14360 · Cited by 42
Opposite angiogenic outcome of curcumin against ischemia and Lewis lung cancer models: in silico, in vitro and in vivo studies
Fan, S., Yan, X., Li, X., Tie, L., Pan, Y., & Li, X. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.019 · Cited by 41
Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array
Abajo, A. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i7.637 · Cited by 41
Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib
Koyama, N., Saito, K., Nishioka, Y., Yusa, W., Yamamoto, N., Yamada, Y., Nokihara, H., Koizumi, F., Nishio, K., & Tamura, T. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-530 · Cited by 40
Clinical value of circulating endothelial cell detection in oncology
Kraan, J., Sleijfer, S., Foekens, J. A., & Gratama, J. W. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.011 · Cited by 40
Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas
Cortes‐Santiago, N., Hossain, M. B., Gabrusiewicz, K. R., Fan, X., Gumin, J., Marini, F. C., Alonso, M. M., Lang, F. F., Yung, W. K. A., Fueyo-Margareto, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7550 · Cited by 40
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies
Pinto, E., Pelizzaro, F., Farinati, F., & Russo, F. P. (2023) · Medicina · doi:10.3390/medicina59061115 · Cited by 43
Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics
Nguyen, Q. D., Agarwal, A. K., Soliman, M. K., Sepah, Y. J., & Diana, V. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52821 · Cited by 39
Fucoidan Inhibits the Growth of Hepatocellular Carcinoma Independent of Angiogenesis
Zhu, C., Cao, R., Zhang, S.-X., Man, Y.-N., & Wu, X.-Z. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/692549 · Cited by 38
Angiogenesis: What can it offer for future medicine?
Cao, Y. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.031 · Cited by 38
Targeting angiopoietin-2 signaling in cancer therapy
Eroglu, Z., Stein, C. A., & Pal, S. K. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.793306 · Cited by 37
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer
Arbab, A. S., & Achyut, B. R. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s102907 · Cited by 38
Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer
Zhang, X., Ju, S., Wang, X., & Cong, H. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00563-w · Cited by 38
Opportunities and Challenges in Tumor Angiogenesis Research
Li, Q., Bromberg-White, J. L., & Qian, C.-N. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394280-7.00006-3 · Cited by 37
Fractal Analysis of CT Perfusion Images for Evaluation of Antiangiogenic Treatment and Survival in Hepatocellular Carcinoma
Hayano, K., Lee, S. H., Yoshida, H., Zhu, A. X., & Sahani, D. V. (2014) · Academic Radiology · doi:10.1016/j.acra.2014.01.020 · Cited by 37
Self-citation
Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer
Bertolini, F., Marighetti, P., Martín-Padura, I., Mancuso, P., Hu‐Lowe, D. D., Shaked, Y., & d’Onofrio, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.007 · Cited by 38
A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases
Leone, J. P., Duda, D. G., Hu, J., Barry, W. T., Trippa, L., Gerstner, E. R., Jain, R. K., Tan, S., Lawler, E., Winer, E. P., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05445-z · Cited by 37
Self-citation
Is VEGF a predictive biomarker to anti-angiogenic therapy?
Otrock, Z. K., Hatoum, H. A., Musallam, K. M., Awada, A. H., & Shamseddine, A. I. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.07.008 · Cited by 37
Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
Abajo, A., Boni, V., López, I., González-Huarriz, M., Bitarte, N., Rodríguez, J., Zárate, R., Bandrés, E., & García‐Foncillas, J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.242 · Cited by 37
Non-invasive imaging of angiogenesis in head and neck squamous cell carcinoma
Jansen, J. F. A., Koutcher, J. A., & Shukla‐Dave, A. (2010) · Angiogenesis · doi:10.1007/s10456-010-9167-z · Cited by 37
T 1 - and T 2 *-Dominant Extravasation Correction in DSC-MRI: Part II—Predicting Patient Outcome after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
Emblem, K. E., Bjørnerud, A., Mouridsen, K., Borra, R., Batchelor, T. T., Jain, R. K., & Sorensen, A. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.39 · Cited by 36
Self-citation
Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations
Tang, P. A., & Moore, M. J. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13502637 · Cited by 36
Novel molecular pathways in Gorham disease: Implications for treatment
Hagendoorn, J., Yock, T. I., Rinkes, I. H. M. B., Padera, T. P., & Ebb, D. H. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24832 · Cited by 35
First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Yap, T. A., Arkenau, H., Camidge, D. R., George, S., Serkova, N. J., Gwyther, S. J., Spratlin, J. L., Lal, R., Spicer, J. F., deSouza, N. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2258 · Cited by 35
Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab
Madsen, C. V., Steffensen, K. D., Olsen, D. A., Waldstrøm, M., Smerdel, M. P., Adimi, P., Brandslund, I., & Jakobsen, A. K. M. (2012) · Journal of Ovarian Research · doi:10.1186/1757-2215-5-23 · Cited by 35
Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies
Barbieri, F., Albertelli, M., Grillo, F., Mohamed, A., Saveanu, A., Barlier, A., Ferone, D., & Florio, T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.015 · Cited by 34
The role of endothelial colony forming cells in kidney cancer’s pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review
Poletto, V., Rosti, V., Biggiogera, M., Guerra, G., Moccia, F. D., & Porta, C. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.005 · Cited by 34
The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
Carvalho, B., Lopes, J. M., Silva, R. P., Peixoto, J., Leitão, D., Soares, P., Fernandes, A. C., Linhares, P., Vaz, R. M., & Lima, J. P. (2021) · Scientific Reports · doi:10.1038/s41598-021-85385-1 · Cited by 34
Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.
Arao, T., MATSUMOTO, K. Y., Furuta, K., Kudo, K., Kaneda, H., Nagai, T., Sakai, K., Fujita, Y., Tamura, D., Aomatsu, K., et al. (2011) · PubMed · Cited by 34
Dehydro-α-lapachone, a plant product with antivascular activity
Garkavtsev, I., Chauhan, V. P., Wong, H. K., Mukhopadhyay, A., Glicksman, M. A., Peterson, R. T., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104225108 · Cited by 34
Self-citation
Pattern recognition of microcirculation with super-resolution ultrasound imaging provides markers for early tumor response to anti-angiogenic therapy
Yin, J., Dong, F., An, J., Guo, T., Cheng, H., Zhang, J., & Zhang, J. (2024) · Theranostics · doi:10.7150/thno.89306 · Cited by 35
Targeting tumor neovasculature in non-small-cell lung cancer
Pallis, A. G., & Syrigos, K. N. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.10.003 · Cited by 33
Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
de Mello, R. A., Costa, B. M., Reis, R. M., & Hespanhol, V. P. (2011) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489212798357994 · Cited by 32
Therapy Monitoring with Functional and Molecular MR Imaging
García‐Figueiras, R., Padhani, A. R., & Baleato‐González, S. (2015) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2015.08.003 · Cited by 33
Characterizing Glioblastoma Heterogeneity via Single-Cell Receptor Quantification
Chen, S., Le, T., Harley, B. A. C., & Imoukhuede, P. I. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00092 · Cited by 33
Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients
Carvalho, B., Lopes, R. G., Linhares, P., Costa, A., Caeiro, C., Fernandes, A. C., Tavares, N., Osório, L., & Vaz, R. M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03404-z · Cited by 33
Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review
Xu, X., Yu, Y., Liu, M., Liang, L., & Liu, T. (2022) · Translational Cancer Research · doi:10.21037/tcr-20-3539 · Cited by 34
Factors regulating capillary remodeling in a reversible model of inflammatory corneal angiogenesis
Mukwaya, A., Peebo, B. B., Xeroudaki, M., Ali, Z., Lennikov, A., Jensen, L. D., & Lagali, N. (2016) · Scientific Reports · doi:10.1038/srep32137 · Cited by 33
Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer
Bruhn, M. A., Townsend, A. R., Lee, C. K., Shivasami, A., Price, T. J., Wrin, J., Arentz, G., Tebbutt, N. C., Hocking, C. M., Cunningham, D., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28698 · Cited by 34
Hepatic Tumors: Region-of-Interest versus Volumetric Analysis for Quantification of Attenuation at CT
Chalian, H., Tochetto, S., Töre, H. F., Rezai, P., & Yaghmai, V. (2012) · Radiology · doi:10.1148/radiol.11110106 · Cited by 32
Tumstatin, a Matrikine Derived from Collagen Type IVα3, is Elevated in Serum from Patients with Non–Small Cell Lung Cancer
Nielsen, S. H., Willumsen, N., Brix, S., Sun, S., Manon‐Jensen, T., Karsdal, M. A., & Genovese, F. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.02.005 · Cited by 32
MR Molecular Imaging of Tumor Vasculature and Vascular Targets
Pathak, A. P., Penet, M., & Bhujwalla, Z. M. (2010) · Advances in genetics · doi:10.1016/s0065-2660(10)69010-4 · Cited by 33
Sensitivity of MRI Tumor Biomarkers to VEGFR Inhibitor Therapy in an Orthotopic Mouse Glioma Model
Farrar, C. T., Kamoun, W. S., Ley, C. D., Kim, Y. R., Catana, C., Kwon, S. J., Rosen, B. R., Jain, R. K., & Sorensen, A. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017228 · Cited by 31
Self-citation
A direct comparison of tumor angiogenesis with 68Ga-labeled NGR and RGD peptides in HT-1080 tumor xenografts using microPET imaging
Shao, Y., Liang, W., Kang, F., Yang, W., Ma, X., Li, G., Zong, S., Chen, K., & Wang, J. (2014) · Amino Acids · doi:10.1007/s00726-014-1788-x · Cited by 31
Nintedanib in ovarian cancer
Khalique, S., & Banerjee, S. N. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1353599 · Cited by 31
Tracing the origins of metastasis
Nguyen, D. X. (2010) · The Journal of Pathology · doi:10.1002/path.2801 · Cited by 31
Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Khan, K. H., Cunningham, D., & Chau, I. (2016) · Current Drug Targets · doi:10.2174/1389450116666150325231555 · Cited by 30
Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes
Pepin, F., Bertos, N., Laferrière, J., Sadekova, S., Souleimanova, M., Zhao, H., Finak, G., Meterissian, S. H., Hallett, M. T., & Park, M. (2012) · Breast Cancer Research · doi:10.1186/bcr3246 · Cited by 30
HypoxamiRs Profiling Identify miR-765 as a Regulator of the Early Stages of Vasculogenic Mimicry in SKOV3 Ovarian Cancer Cells
Salinas-Vera, Y. M., Gallardo‐Rincón, D., García-Vázquez, R., la Cruz, O. N. H.-D., Marchat, L. A., González-Barrios, J. A., Ruíz‐García, E., Vázquez‐Calzada, C., Contreras-Sanzón, E., Resendiz-Hernández, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00381 · Cited by 30
In vitroeffects ofYunnan Baiyaoon canine hemangiosarcoma cell lines
Wirth, K. A., Kow, K. Y., Salute, M. E., Bacon, N. J., & Milner, R. J. (2014) · Veterinary and Comparative Oncology · doi:10.1111/vco.12100 · Cited by 30
Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer
Duda, D. G. (2012) · ISRN Cell Biology · doi:10.5402/2012/587259 · Cited by 31
Self-citation
Applications of Molecular Imaging
Galbán, C. J., Galbán, S., Dort, M. E. V., Luker, G. D., Bhojani, M. S., Rehemtulla, A., & Ross, B. D. (2010) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385071-3.00009-5 · Cited by 30
Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer
Yang, F., Jin, C., Jiang, Y., Li, J., Yang, D., & Fu, D. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.171 · Cited by 29
A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma
Ramaswami, R., Uldrick, T. S., Polizzotto, M. N., Wyvill, K. M., Goncalves, P. H., Widell, A., Lurain, K. A., Steinberg, S. M., Figg, W. D., Tosato, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3528 · Cited by 29
Necrosis in the Tumor Microenvironment and Its Role in Cancer Recurrence
Karsch-Bluman, A., & Benny, O. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35727-6_6 · Cited by 33
Circulating Endothelial Cells and Their Subpopulations: Role as Predictive Biomarkers in Antiangiogenic Therapy for Colorectal Cancer
Manzoni, M., Comolli, G., Torchio, M., Mazzini, G., & Danova, M. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.002 · Cited by 29
An integrative paradigm to impart quality to correlative science
Kalos, M. D. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-26 · Cited by 29
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status
Alfonso, P. G., Grande, E., Polo, E., Afonso, R., Reina, J. J., Jorge, M., Campos, J. M., Martínez, V., Ángeles, C., & Montagut, C. O. (2014) · Angiogenesis · doi:10.1007/s10456-014-9433-6 · Cited by 29
Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions
Thakur, A., Rana, M., Mishra, A., Kaur, C., Pan, C., & Nepali, K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116472 · Cited by 29
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma
Thomas, A. A., Fisher, J. L., Hampton, T. H., Christensen, B. C., Tsongalis, G. J., Rahme, G. J., Whipple, C. A., Steel, S. E., Davis, M. C., Gaur, A. B., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1941-3 · Cited by 28
HOX Transcript Antisense RNA HOTAIR Abrogates Vasculogenic Mimicry by Targeting the AngiomiR-204/FAK Axis in Triple Negative Breast Cancer Cells
Lozano-Romero, A., la Vega, H. A., Terrones-Gurrola, M. C. D. R., Marchat, L. A., Hernández‐Sotelo, D., Salinas-Vera, Y. M., Ramos‐Payán, R., Silva-Cázares, M. B., Núñez-Olvera, S. I., la Cruz, O. N. H.-D., et al. (2020) · Non-Coding RNA · doi:10.3390/ncrna6020019 · Cited by 28
Tumour angiogenesis normalized by myo‐inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response
Hafny‐Rahbi, B. E., Brodaczewska, K. K., Collet, G., Majewska, A., Klimkiewicz, K., Delalande, A., Grillon, C., & Kiéda, C. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16399 · Cited by 27
In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines
Lyles, S. E., Milner, R. J., Kow, K. Y., & Salute, M. E. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00335.x · Cited by 28
Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer
Manzoni, M., Mariucci, S., Delfanti, S., Rovati, B., Ronzoni, M., Loupakis, F., Brugnatelli, S., Tinelli, C., Villa, E., Falcone, A., et al. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1190-6 · Cited by 28
A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal
Mastri, M., Tracz, A., Lee, C. R., Dolan, M., Attwood, K., Christensen, J. G., Liu, S., & Ebos, J. M. L. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.017 · Cited by 28
Translational research on drug development and biomarker discovery for hepatocellular carcinoma
Chew, V., Chuang, C.-H., & Hsu, C. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01011-y · Cited by 29
Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value
Zhu, A. X., Duda, D. G., Ancukiewicz, M., di Tomaso, E., Clark, J. W., Miksad, R. A., Fuchs, C. S., Ryan, D. P., & Jain, R. K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0515 · Cited by 27
Self-citation
Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment
Gaddy, T. D., Wu, Q., Arnheim, A. D., & Finley, S. D. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005874 · Cited by 28
Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance
Wimberger, P., Chebouti, I., Kasimir‐Bauer, S., Lachmann, R., Kuhlisch, E., Kimmig, R., Ergün, S., & Kuhlmann, J. D. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.574 · Cited by 27
Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies
Basu, B., Biswas, S., Wrigley, J., Sirohi, B., & Corrie, P. G. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.135 · Cited by 27
Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Budolfsen, C., Faber, J., Grimm, D. G., Krüger, M., Bauer, J. W., Wehland, M., Infanger, M., & Magnusson, N. E. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190130165810 · Cited by 27
Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrin αvβ3–Targeted Radiotracer 99mTc-3P-RGD2 99mTc-3P-RGD2: An Integrin αvβ3–Targeted Radiotracer to Monitor Linifanib Therapy
Ji, S., Zhou, Y., Voorbach, M. J., Shao, G., Zhang, Y., Fox, G. B., Albert, D. H., Luo, Y., Liu, S., & Mudd, S. R. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.202622 · Cited by 26
Neuroimaging Findings of the Post-Treatment Effects of Radiation and Chemotherapy of Malignant Primary Glial Neoplasms
Mamlouk, M. D., Handwerker, J., Ospina, J., & Hasso, A. N. (2013) · The Neuroradiology Journal · doi:10.1177/197140091302600405 · Cited by 26
The G-Protein–Coupled Receptor CLR Is Upregulated in an Autocrine Loop with Adrenomedullin in Clear Cell Renal Cell Carcinoma and Associated with Poor Prognosis
Nikitenko, L. L., Leek, R., Henderson, S. R., Pillay, N., Turley, H., Generali, D., Gunningham, S. P., Morrin, H. R., Pellagatti, A., REES, M. C. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1712 · Cited by 26
Antiangiogenic therapy for breast cancer
Nielsen, D. L., Andersson, M., Andersen, J. L., & Kamby, C. (2010) · Breast Cancer Research · doi:10.1186/bcr2642 · Cited by 26
Advancements in antibody-drug conjugates as cancer therapeutics
Fong, J. Y., Phuna, Z. X., Chong, D., Heryanto, C. M., Low, Y. S., Oh, K. C., Lee, Y., Ng, A. W. R., In, L. L. A., & Teo, M. Y. M. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.01.007 · Cited by 31
Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer
Mirone, G., Shukla, A. K., & Marfè, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.012 · Cited by 28
Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors.
Madsen, C. V., Steffensen, K. D., Olsen, D. A., Waldstrøm, M., Søgaard, C. H., Brandslund, I., & Jakobsen, A. K. M. (2012) · PubMed · Cited by 24
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer
Ryan, A. J. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1022 · Cited by 24
The Role of Angiogenesis Inhibitors in the Management of Melanoma
Zaki, K. A., Basu, B., & Corrie, P. G. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612798919240 · Cited by 24
Cancer Biology
Cree, I. A. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-080-5_1 · Cited by 24
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma
Horowitz, N. S., Penson, R. T., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Cohen, K. S., Berlin, S. T., Krasner, C. N., Moses, M. A., et al. (2011) · Clinical Ovarian Cancer · doi:10.1016/j.cloc.2011.04.003 · Cited by 23
Self-citation
Multiple parameters from ultrafast dynamic contrast-enhanced magnetic resonance imaging to discriminate between benign and malignant breast lesions: Comparison with apparent diffusion coefficient
Cao, Y. J., Wang, X., Shi, J., Zeng, X., Du, L., Li, Q., Nickel, D. M., Zhou, X., & Zhang, J. (2023) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2023.01.006 · Cited by 23
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
Asahina, H., Tamura, Y., Nokihara, H., Yamamoto, N., Seki, Y., Shibata, T., Goto, Y., Tanioka, M., Yamada, Y., Coates, A., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1846-6 · Cited by 23
High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Berković, M. C., Čaćev, T., Ivković, T. C., Marout, J., Ulamec, M., Zjačić-Rotkvić, V., & Kapitanović, S. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.01.013 · Cited by 23
Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer
Huang, Y., & Carbone, D. P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.003 · Cited by 22
Peering into the aftermath: The inhospitable host?
Kerbel, R. S., & Ebos, J. M. L. (2010) · Nature Medicine · doi:10.1038/nm1010-1084 · Cited by 22
A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Bender, J. G., Blaney, S. M., Borinstein, S. C., Reid, J. M., Baruchel, S., Ahern, C. H., Ingle, A. M., Yamashiro, D. J., Chen, A. P., Weigel, B. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0078 · Cited by 22
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)
Avallone, A., Piccirillo, M. C., Aloj, L., Nasti, G., Delrio, P., Izzo, F., Gennaro, E. D., Tatangelo, F., Granata, V., Cavalcanti, E., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2102-y · Cited by 22
Genomic Markers of Resistance to Targeted Treatments in Gastric Cancer: Potential New Treatment Strategies
Raimondi, A., Nichetti, F., Peverelli, G., Bartolomeo, M. D., de Braud, F., & Pietrantonio, F. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0077 · Cited by 22

Authors: Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G.
Affiliations: Harvard University (US)
Duke Medical Center (US)
Corresponding author: Jain, Rakesh K.
ORCID: Duda, Dan G.
Willett, Christopher G.
Zhu, Andrew X.
Batchelor, Tracy T.
Sorensen, A. Gregory
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2009-06
Volume: 6
Issue: 6
Pages: 327-338
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2009.63
PMC: PMC3057433
OpenAlex: W1993016882
Cited by: 572
References: 83
Citations by year: 2026: 10 · 2025: 14 · 2024: 9 · 2023: 15 · 2022: 11 · 2021: 19 · 2020: 26 · 2019: 17 · 2018: 25 · 2017: 33 · 2016: 35 · 2015: 38 · 2014: 44 · 2013: 57 · 2012: 67
FWCI: 5.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA115767, R01CA57683, R01 CA 85140, R21CA117079, R01CA085140, R01CA057683, R21-CA 99237, P01CA080124, R21CA099237, R01CA126642, K24CA125440, R01CA129371, P01-CA-80124)
National Center for Research Resources (P41-RR-14075, M01RR001066, P41RR014075, M01-RR01066)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: anti-angiogenic therapy, biomarkers, treatment response, drug resistance, patient selection, VEGF polymorphisms, type IV collagen, pharmacodynamic biomarkers, imaging biomarkers, Ktrans, placental growth factor, stromal cell-derived factor-1α, interleukin-6, tumor stroma
MeSH terms: Humans, Neoplasms, Neovascularization, Pathologic, Biomarkers, Tumor, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Biomarkers of response and resistance to antiangiogenic therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks